Mifanertinib is a small-molecule kinase inhibitor investigated for its activity against members of the epidermal growth factor receptor (EGFR) family, including EGFR and HER2. It is also known by the development name mefatinib and has been investigated as an oncology-focused targeted therapy candidate. PubChem identifies Mifanertinib as an antineoplastic agent and protein kinase inhibitor under the ATC classification L01EH05.
Mifanertinib is a chemically defined small molecule with the molecular formula C₂₁H₁₉ClF₃N₅O₂ and molecular weight 465.9 g/mol. Its CAS Registry Number is 1639014-72-4. The compound contains a quinazoline core substituted with a difluoromethoxy group, a chlorofluorophenylamino moiety and a dimethylaminobutenamide side chain.
As an investigational oncology compound, Mifanertinib API is relevant to pharmaceutical research, drug-development programs, analytical research and formulation-development activities. Its targeted kinase-inhibitor profile makes it of interest in research involving receptor tyrosine kinase signaling and molecularly targeted cancer therapies.
Mifanertinib is a synthetic small-molecule compound belonging to the quinazoline class of kinase inhibitors. It has been investigated as an irreversible tyrosine kinase inhibitor targeting EGFR-family signaling. Research programs have evaluated its activity against EGFR and HER2-related pathways.
The compound is structurally distinct from conventional reversible kinase inhibitors because its chemical architecture incorporates an electrophilic acrylamide-type side chain that is associated with covalent kinase-targeting activity.
Mifanertinib has been investigated in oncology research, particularly in settings where aberrant EGFR/HER2 signaling may contribute to tumor growth and survival.
For pharmaceutical research organizations, Mifanertinib API can be relevant for analytical characterization, preclinical research, formulation development and investigational drug-development programs, subject to applicable regulatory requirements.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |